Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.59 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.57 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.57 |
| ▸ | FABP3 | P05413 | 1/20 | 0.57 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.54 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.54 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.54 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15526366 | 1.00 | ENPP2 (0.59) | ENPP2LPAR3LPAR1SMN1; SMN2PLA2G2C | |
| SCHEMBL6254776 | 0.94 | PRKCA (0.56) | ENPP2LPAR3LPAR1SMN1; SMN2FABP3 | |
| SCHEMBL7204294 | 0.94 | PRKCA (0.56) | ENPP2LPAR3LPAR1SMN1; SMN2FABP3 | |
| SCHEMBL14659956 | 0.94 | PRKCA (0.56) | ENPP2LPAR3LPAR1SMN1; SMN2FABP3 | |
| SCHEMBL19629017 | 0.94 | ENPP2 (0.57) | ENPP2LPAR3LPAR1SMN1; SMN2FABP3 | |
| SCHEMBL16714278 | 0.93 | ENPP2 (0.64) | ENPP2LPAR3LPAR1 | |
| SCHEMBL190727 | 0.93 | ENPP2 (0.64) | ENPP2LPAR3LPAR1 | |
| SCHEMBL18719361 | 0.91 | ENPP2 (0.63) | ENPP2LPAR3LPAR1SMN1; SMN2FABP3 | |
| SCHEMBL2126025 | 0.88 | PRKCE (0.61) | ENPP2LPAR3 | |
| SCHEMBL3645476 | 0.87 | ENPP2 (0.57) | ENPP2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098344-A1 | DRUG CARRIER | NIPPON SHINYAKU CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-2292270-A1 | DRUG CARRIER | Nippon Shinyaku Co., Ltd. (JP) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098344-A1 | DRUG CARRIER | SLC10A1, NPC1L1, SGMS1 | ENPP2 501/4885LPAR3 78/4885LPAR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.